Biotechnology News
US biotech ImmunityBio has secured $75 million through a direct offering with a single institutional investor, according to a statement released Tuesday. 10 April 2025
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 10 April 2025
Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, has announced its launch alongside a $121million financing. 9 April 2025
Exclusive
Company Spotlight
A biopharmaceutical company developing novel therapies for retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Most Read
In Brief
Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated top-line results from its second Phase III trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD. 31 March 2025
Mergers and Acquisitions
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 10 April 2025
7 April 2025
29 March 2025
27 March 2025
Editor's Pick
29 May 2024
13 June 2024
Boardroom
Dutch rare diseases biotech firm ProQR Therapeutics today announced the appointment of Dr Cristina Lopez Lopez as chief medical officer (CMO). 14 April 2025
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze